common side effects of glp-1 receptor agonists Adverse Struggling with GLP-1 therapy side

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

However, most (59%) of same those employers say their cost for the drugs has exceeded expectations

In clinical practice, drug selection should therefore prioritize factors such as tolerability, safety profile, adherence, cost, and patient preference rather than expecting major differences in cardiovascular efficacy.

However, the cost of sitagliptin and the need for more data may restrict its use

These medications enable cause-specific management of obesity complications.